On May 18th, the inaugural multi-center clinical trial for China's pioneering 128-channel fully implantable brain-computer interface (BCI) system was officially launched at Beijing Tiantan Hospital, affiliated with Capital Medical University. This groundbreaking trial involves the collaboration of 11 medical institutions nationwide, with an ambitious goal to recruit 32 participants within a six-month timeframe.

The innovative system leverages intracortical implantable flexible electrodes and a highly integrated, fully implantable signal collector, specifically designed to facilitate hand function rehabilitation in patients suffering from tetraplegia. Moreover, the system holds promising potential for future applications in treating conditions such as spinal cord injuries, strokes, and amyotrophic lateral sclerosis (ALS).

Fueled by this significant development, stocks related to the brain-computer interface concept experienced a surge in activity on the 19th. Notably, Bycon's stock price soared by over 10%, closely followed by gains in other related stocks, including those of Sanbo Brain Hospital.